| Particulars (Rupees in Crores.) | Sept-2025 | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 |
|---|---|---|---|---|---|
Gross Sales | 1,957.8 | 1,878.9 | 1,915.8 | 1,813.7 | 1,742.2 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,957.8 | 1,878.9 | 1,915.8 | 1,813.7 | 1,742.2 |
Other Operating Income | 8.6 | 21.8 | 13 | 8 | 10.1 |
Other Income | 9.8 | 12 | 11.9 | 9.2 | 21.7 |
Total Income | 1,976.2 | 1,912.7 | 1,940.7 | 1,830.9 | 1,774 |
Total Expenditure | 1,630.9 | 1,611.2 | 1,586.8 | 1,553.5 | 1,477.2 |
PBIDT | 345.3 | 301.5 | 353.9 | 277.4 | 296.8 |
Interest | 50.2 | 49 | 52.7 | 55.6 | 61 |
PBDT | 295.1 | 252.5 | 301.2 | 221.8 | 235.8 |
Depreciation | 104.8 | 98.1 | 95.2 | 91.3 | 91.4 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 36.1 | 37.5 | 114.8 | 32.3 | 40 |
Deferred Tax | 34.3 | 14.4 | -60.1 | -2.5 | 1.9 |
Reported Profit After Tax | 119.9 | 102.5 | 151.3 | 100.7 | 102.5 |
Minority Interest After NP | -0.4 | -0.4 | -2.3 | -0.2 | -0.3 |
Net Profit after Minority Interest | 120.3 | 102.9 | 153.6 | 100.9 | 102.8 |
Extra-ordinary Items | -3.65 | 0 | -1.46 | -14.22 | -10.08 |
Adjusted Profit After Extra-ordinary item | 123.95 | 102.9 | 155.06 | 115.12 | 112.88 |
EPS (Unit Curr.) | 7.59 | 6.49 | 9.71 | 6.37 | 6.47 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 15.8 | 15.8 | 15.8 | 15.8 | 15.8 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 17.63 | 16.04 | 18.47 | 15.29 | 17.03 |
PBDTM(%) | 15.07 | 13.43 | 15.72 | 12.22 | 13.53 |
PATM(%) | 6.12 | 5.45 | 7.89 | 5.55 | 5.88 |
The API division posted a turnover of ₹609 Crore for the financial year ended March 2025. This was 8.35% of the company’s consolidated revenue.
Here are some of the stocks that may see significant price movement today: Torrent Power, DCM Shriram, Jubilant Pharmova, etc.
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
